Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Sborov, Douglas W  [Clear All Filters]
2023
Voorhees PM, Sborov DW, Laubach J, Kaufman JL, Reeves B, Rodríguez C, Chari A, Silbermann R, Costa LJ, Anderson LD, et al. Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial. Lancet Haematol. 2023.
Trunk AD, Patel SS, Prchal JT, Sborov DW, Zander AR, Lee CJ. Allogeneic stem cell transplant for multiple myeloma & myelofibrosis with split-dose busulfan, fludarabine & cyclophosphamide. Leuk Res Rep. 2023;20:100388.
Davis JA, Sborov DW, Wesson W, Julian K, Abdallah A-O, McGuirk JP, Ahmed N, Hashmi H. Efficacy and Safety of CD34+ Stem Cell Boost for Delayed Hematopoietic Recovery After BCMA Directed CAR T-cell Therapy. Transplant Cell Ther. 2023.
Baljevic M, Sborov DW. Understanding risks and refining strategies for thromboembolism prophylaxis in hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2023.
2022
Fatoki RAyoolu, Koehn K, Kelkar A, Hadidi SAl, Mehra N, Mian H, Landgren O, Kazandjian D, Hoffman J, Sborov DW, et al. Global Myeloma Trial Participation and Drug Access in the Era of Novel Therapies. JCO Glob Oncol. 2022;8:e2200119.
Chhabra S, Callander N, Watts NL, Costa LJ, Thapa B, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodríguez C, et al. Stem cell mobilization yields with daratumumab and lenalidomide-containing quadruplet induction therapy in newly diagnosed multiple myeloma: findings from the MASTER and GRIFFIN trials. Transplant Cell Ther. 2022.
2018
Cho YKyoung, Irby DJ, Li J, Sborov DW, Mould DR, Badawi M, Dauki A, Lamprecht M, Rosko AE, Fernandez S, et al. Pharmacokinetic-Pharmacodynamic Model of Neutropenia in Patients With Myeloma Receiving High-Dose Melphalan for Autologous Stem Cell Transplant. CPT Pharmacometrics Syst Pharmacol. 2018.